PDF(Pubmed)
Abstract：
Myelodysplastic Neoplasms (MDS) have been traditionally studied through the assessment of blood counts, cytogenetics, and morphology. In recent years, the introduction of molecular assays has improved our ability to diagnose MDS. The role of Measurable (minimal) Residual Disease (MRD) in MDS is evolving, and molecular and flow cytometry techniques have been used in several studies. In this review, we will highlight the evolving concept of MRD in MDS, outline the various techniques utilized, and provide an overview of the studies reporting MRD and the correlation with outcomes.
摘要：
骨髓增生异常肿瘤（MDS）传统上是通过血细胞计数评估来研究的，细胞遗传学,和形态学。近年来,分子检测的引入提高了我们诊断MDS的能力。可测量（最小）残留疾病（MRD）在MDS中的作用正在演变，分子和流式细胞术技术已用于多项研究。在这次审查中,我们将强调MDS中MRD的不断发展的概念，概述所使用的各种技术，并概述报告MRD的研究以及与结局的相关性。
